Lung Cancer Dispatch
4.5K views | +0 today
Follow
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Suggested by Cancer Commons
Scoop.it!

Four-Drug Combination Shown to Be Safe and Effective for NSCLC

Four-Drug Combination Shown to Be Safe and Effective for NSCLC | Lung Cancer Dispatch | Scoop.it

A combination of the drugs carboplatin (Paraplatin), paclitaxel (Taxol/Abraxane), cetuximab (Erbitux), and bevacizumab (Avastin) has demonstrated effectiveness against non-small cell lung cancer (NSCLC) in a phase II clinical trial. One hundred two patients with advanced non-squamous NSCLC received the four-drug combo as a first-line treatment. Tumors shrank in 56% of patients and stopped growing in an additional 21%. Patients went an average of 7 months without their cancer progressing; the average survival time was 15 months. Four treatment-related deaths occurred, including two due to hemorrhage (heavy bleeding), which can be a rare but serious effect of Avastin treatment. This side effect profile was within the predefined safety margin. A phase III trial further investigating this drug combination for NSCLC is currently enrolling participants.

Cancer Commons's insight:

MedwireNews  |  Dec 2, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Erbitux-Avastin Combination Plus Chemotherapy in Lung Cancer Is Safe and Effective

Erbitux-Avastin Combination Plus Chemotherapy in Lung Cancer Is Safe and Effective | Lung Cancer Dispatch | Scoop.it

Combining cetuximab (Erbitux), bevacizumab (Avastin), and traditional chemotherapy in patients with non-small cell lung cancer (NSCLC) appeared to be safe and effective in a phase II clinical trial. Patients with advanced non-squamous NSCLC received Erbitux and Avastin in addition to carboplatin (Paraplatin) and paclitaxel (Taxol/Abraxane) as first-line treatment, followed by maintenance treatment with Erbitux and Avastin. Tumors shrank in 56% of patients and stopped growing in an additional 21%. Serious side effects were relatively rare; the rate was comparable to that of either Erbitux or Avastin alone. Both Erbitux and Avastin have shown efficacy in NSCLC by themselves, but may be more effective when given together. An ongoing phase III clinical trial will further investigate this drug combination.

Cancer Commons's insight:

Medical News Today | Nov 5, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Gene Variations May Predict Outcomes in Non-Small Cell Lung Cancer

Gene Variations May Predict Outcomes in Non-Small Cell Lung Cancer | Lung Cancer Dispatch | Scoop.it

Variations in two genes called CXCR-2 and PAR-1 may predict how a person with non-small cell lung cancer (NSCLC) will fare. A study of over 200 NSCLC patients found that those with certain versions of the genes were likely to experience faster disease progression and shorter survival, especially if patients had squamous cell carcinoma (SCC). Both genes are involved in tumor angiogenesis, that is, the growth of new blood vessels that enable tumors to expand. In the future, testing for these high-risk gene variants may help identify good candidates for anti-angiogenesis treatments like bevacizumab (Avastin).

Cancer Commons's insight:

Lung Cancer | Mar 30, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Positive Results For Vargatef in Lung Cancer Study

Positive Results For Vargatef in Lung Cancer Study | Lung Cancer Dispatch | Scoop.it

New clinical trial results suggest that adding the drug nintedanib (Vargatef) to second-line chemotherapy can improve survival for some patients with non-small cell lung cancer (NSCLC). Patients with advanced NSCLC whose cancer had progressed after first-line chemotherapy received either Vargatef and the chemotherapy drug docetaxel (Taxotere) or Taxotere alone. On the whole, Vargatef was associated with slightly longer times without worsening of the cancer (3.4 months vs 2.7 in the Taxotere-only group), but no improvement in overall survival. However, in patients with lung adenocarcinoma, a subtype of NSCLC, the addition of Vargatef improved overall survival by over 2 months (12.6 months vs 10.3 with Taxotere alone). Vargatef disrupts the formation of new blood vessels that feed growing tumors.

Cancer Commons's insight:

Clinical Oncology News  |  Oct, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

New Molecular Target May Lead to Cancer Drugs that Suffocate Tumors

New Molecular Target May Lead to Cancer Drugs that Suffocate Tumors | Lung Cancer Dispatch | Scoop.it

Researchers have identified a compound that may cut off tumors' oxygen supply. Because they grow so rapidly, tumors eventually outgrow the ability of the surrounding blood vessels to transport enough oxygen and nutrients to them. In response to low oxygen levels, tumors trigger the formation of new blood vessels to keep them supplied. Now, scientists have discovered a protein, HIF-1, that acts as a 'master switch' that turns on hundreds of other genes involved in forming these new blood vessels. They then identified a new compound called cyclo-CLLFVY that blocked HIF-1 in cultured cancer cells. Researchers now hope to develop cyclo-CLLFVY into a drug that can prevent tumors from getting the oxygen they need to survive.

Cancer Commons's insight:

Cancer Research UK | Jul 26, 2013

more...
Cancer Commons's curator insight, August 1, 2013 2:47 PM

Cancer Research UK | Jul 26, 2013

Cancer Commons's curator insight, August 1, 2013 2:47 PM

Cancer Research UK | Jul 26, 2013

Cancer Commons's curator insight, August 1, 2013 2:47 PM

Cancer Research UK | Jul 26, 2013